Redaporfin (Synonyms: LUZ11; F2BMet) |
Catalog No.GC62293 |
Redaporfin (LUZ11) actÚa como un potente fotosensibilizador. La redaporfina provoca efectos antineoplÁsicos directos, asÍ como destrucciÓn inmunodependiente indirecta de lesiones malignas.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1224104-08-8
Sample solution is provided at 25 µL, 10mM.
Redaporfin (LUZ11) acts as a potent photosensitizer. Redaporfin causes direct antineoplastic effects as well as indirect immune‐dependent destruction of malignant lesions[1].
The combination photodynamic therapy (PDT) with Redaporfin (5μM) induces a reduction in the abundance of several Golgi apparatus (GA) proteins such as Golgi brefeldin A-resistant guanine nucleotide exchange factor 1 (GBF1), golgin subfamily A member 2 (GOLGA2), and galactosyltransferase 1 (GALT1), as well as that of two ER proteins, eukaryotic translation initiation factor 2-alpha (eIF2α) kinase 3 (EIF2AK3) and protein disulfide-isomerase A3 (PDIA3). In contrast, there is no major decrease in mitochondrial import receptor subunit TOM20 homolog (TOMM20) or in the cytoskeleton protein β-actin[1].
[1]. LÍgia C Gomes-da-Silva, et al. Photodynamic therapy with redaporfin targets the endoplasmic reticulum and Golgi apparatus. EMBO J. 2018 Jul 2;37(13):e98354.
Average Rating: 5
(Based on Reviews and 20 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *